Covid-19: a laboratory subcontractor of Pfizer accused of failures during trials on the vaccine – LCI

A testimony that causes confusion. Cited by an article in British Medical Journal (BMJ), a former employee of a subcontractor of the pharmaceutical group Pfizer, responsible for carrying out a small part of the clinical trials of its anti-Covid 19 vaccine, says that the latter committed numerous lapses during these tests.

The Texan group Ventavia, which specializes in conducting clinical trials and commissioned last year by Pfizer to assess the effectiveness of its anti-Covid vaccine, in particular “falsified data” and “delayed in monitoring side effects”, according to this article published Tuesday.

The main source of the article in BMJ is a former Ventavia employee, Brook Jackson, who worked there for two weeks during the Pfizer-BioNTech vaccine trials, before being fired. She says she has witnessed many shortcomings and accuses Ventavia in particular of having, through its inconsistencies in labeling, compromised the double-blind allocation of the vaccine, an essential procedure for evaluating the effectiveness of a treatment compared to a placebo. She makes sure that neither patients nor caregivers know whether it is one or the other.

Brook Jackson cites other shortcomings, such as the fact that the vaccines were not stored at the right temperature and said that she had communicated this to the American health authorities, the FDA, which she said took note of her report, but did not follow up.

Contacted by AFP, the FDA refrained from commenting on this file, but assured of “his full confidence in the data which led to support the authorization of the Pfizer-BioNTech vaccine”. According to another source cited by the BMJ, this anonymous, Pfizer dispatched an audit of Ventavia, once informed of “problems” in the course of the tests. Neither Pfizer nor Ventavia immediately responded to AFP’s requests.

Ventavia played only a small role in the trials of this vaccine, developed by Pfizer with BioNTech. The Texan group has conducted tests on a thousand people, while the vaccine has, in total, been evaluated on about 44,000 people around the world. These trials, demonstrating particularly high efficacy, have led to the authorization of the vaccine in many countries, such as the United States and the countries of the European Union.